SCHEMBL10123565

SCHEMBL10123565

Cc1c(F)cc2ccccn12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 6/20 0.39
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 3/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
L3MBTL1 Q9Y468 6/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
ATM Q13315 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
CHEK1 O14757 1/20 0.36
LIMK1 P53667 1/20 0.36
MAPK14 Q16539 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16363139 0.75 MAPT (0.46) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL1435606 0.72 MAPT (0.57) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL22792389 0.72 MAPT (0.60) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL16363145 0.71 L3MBTL1 (0.35) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL16363134 0.71 L3MBTL1 (0.38) POLBMAPTALDH1A1KDM4ERAB9A
SCHEMBL11969946 0.71 MAPT (0.37) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL1664859 0.71 ALOX15 (0.35) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL344255 0.69 L3MBTL1 (0.59) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL13169604 0.68 CYP1A2 (0.39) MAPTALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL16363725 0.67 KDM4E (0.45) POLBMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748452-B2 Indolizine derivative and use thereof for medical purposes KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-06-10 US disclosed
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES XDH, INMT, PON1 POLB 4007/4885MEN1 2393/4885KMT2A 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.